Valuation: Ocugen, Inc.

Market Cap 444M 7.61B 385M 359M 329M 619M 42.37B 629M 4.22B 1.65B 21.2B 1.67B 1.63B 70.59B P/E 2026 *
-5.21x
P/E 2027 * -4.9x
Enterprise Value 382M 6.54B 330M 309M 282M 532M 36.41B 540M 3.62B 1.42B 18.21B 1.43B 1.4B 60.66B EV / Sales 2026 *
75.1x
EV / Sales 2027 * 178x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 week-7.25%
Current month+3.97%
1 month-17.31%
3 months-16.50%
6 months-13.97%
Current year-14.34%
1 week 21.5
Extreme 21.5
22
1 month 20.68
Extreme 20.68
25.2
Current year 19.9
Extreme 19.9
45.5
1 year 18.7
Extreme 18.7
45.5
3 years 6.05
Extreme 6.05
45.5
5 years 6.05
Extreme 6.05
335
10 years 6.05
Extreme 6.05
335
Manager TitleAgeSince
Chief Executive Officer 62 2019-09-26
Director of Finance/CFO - 2026-02-08
Chief Operating Officer - 2026-02-28
Director TitleAgeSince
Chairman 62 2019-09-26
Director/Board Member 59 2013-08-31
Director/Board Member 59 2019-08-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-7.25% - - 444M
-0.57%+3.85%+6.76%+16.75% 50.03B
+0.89%+13.44%+491.34%+594.30% 44.36B
+3.08%+14.42%+24.57%+81.39% 40.82B
+1.38%+3.70%+34.54%+9.11% 39.83B
+0.85%+10.32%+21.22%+47.64% 32.51B
+0.08%+5.00% - - 16.85B
+1.99%+5.08%+38.70%+125.08% 16.81B
-1.03%+0.81%+4.71%+20.45% 14.05B
+3.56%+19.98%+86.23%+27.29% 13.22B
Average +1.02%+279.70%+88.51%+115.25% 29.83B
Weighted average by Cap. +1.05%+295.03%+107.54%+139.83%

Financials

2026 *2027 *
Net sales 5.08M 87.14M 4.4M 4.11M 3.76M 7.08M 485M 7.2M 48.24M 18.93M 243M 19.09M 18.67M 808M 2.5M 42.85M 2.16M 2.02M 1.85M 3.48M 238M 3.54M 23.72M 9.31M 119M 9.39M 9.18M 397M
Net income -85.28M -1.46B -73.83M -69.01M -63.07M -119M -8.13B -121M -809M -318M -4.07B -320M -313M -13.55B -93.41M -1.6B -80.87M -75.59M -69.08M -130M -8.91B -132M -886M -348M -4.46B -351M -343M -14.84B
Net Debt -62.5M -1.07B -54.11M -50.57M -46.22M -87.1M -5.96B -88.46M -593M -233M -2.98B -235M -230M -9.93B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
26-08-07 MX$21.50 0.00% 8
26-08-06 MX$21.50 -4.44% 55
26-08-04 MX$22.50 -2.93% 86
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.310USD
Average target price
12.17USD
Spread / Average Target
+828.75%

Quarterly revenue - Rate of surprise